Completed PHASE1 INTERVENTIONAL 2-arm NCT00965978

A Study to Evaluate Food Effect on ONO-5920/YM529 Intermittent Formulation

A Study to Evaluate Food Effect on Pharmacokinetics Parameters After Administration of ONO-5920/YM529 Intermittent Formulation

Sponsor: Astellas Pharma Inc

Conditions Bone Diseases Osteoporosis Osteoporosis, Postmenopausal

Interventions ONO-5920 / YM529

Updated 5 times since 2017 Last updated: Oct 1, 2009 Started: Jul 31, 2009 Primary completion: Sep 30, 2009 Completion: Sep 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00965978, this PHASE1 trial focuses on Bone Diseases and Osteoporosis and remains completed. Sponsored by Astellas Pharma Inc, it has been updated 5 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Jul 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Astellas Pharma Inc
Ono Pharma USA Inc

Data source: Astellas Pharma Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Kantou, Japan